Compare IPW & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPW | LSTA |
|---|---|---|
| Founded | 2018 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1M | 15.9M |
| IPO Year | 2021 | 2000 |
| Metric | IPW | LSTA |
|---|---|---|
| Price | $1.27 | $1.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 980.9K | 106.8K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | N/A | ★ N/A |
| Revenue | $19,956,938.00 | ★ $35,283,868.00 |
| Revenue This Year | $596.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.18 | $0.96 |
| 52 Week High | $1,836,562,600.00 | $5.07 |
| Indicator | IPW | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 25.40 | 56.67 |
| Support Level | $0.18 | $1.23 |
| Resistance Level | $1.57 | $1.28 |
| Average True Range (ATR) | 0.36 | 0.12 |
| MACD | 14.78 | 0.04 |
| Stochastic Oscillator | 3.22 | 59.47 |
iPower Inc is a technology-enabled commerce infrastructure company providing supply chain, logistics, fulfillment, warehousing and procurement solutions for e-commerce and distribution channels. Its product portfolio includes hydroponic products, gardening supplies, home goods and related accessories, with gardening and home products. Geographically, the company generates majority of its revenue from the United States, followed by Canada and other international markets.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.